RxDoctor Payments Data

Erica Patrick, MD

Neurology · Rochester, NYNPI 1619172327

Payments from drug & device makers

$1,123in general payments, 2019–2025

Across 94 payments — averaging $11.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$839
  • Bristol Myers Squibb$83
  • Acorda Therapeutics, Inc$43
  • TG Therapeutics, Inc.$40
  • Jazz Pharmaceuticals Inc.$35
  • Lilly USA, LLC$28
  • plus $55 from 3 others

What the payments were for

  • Speaking & faculty fees$434%
  • Food & beverage$1,08096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,123 in reported general payments places this provider in the 45th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$54,652
Medicare patients
134
Services billed
2,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate23$215,942
Dimethyl Fumarate28$47,688
Aimovig AutoinjectorErenumab-Aooe56$43,501
KeppraLevetiracetam12$37,169
Nurtec OdtRimegepant Sulfate22$22,931
Glatiramer Acetate13$18,026
Carbidopa-LevodopaCarbidopa/Levodopa360$17,273
UbrelvyUbrogepant21$15,397
Emgality PenGalcanezumab-Gnlm11$15,306
Ajovy AutoinjectorFremanezumab-Vfrm21$14,459
Pregabalin105$7,928
Mycophenolate Mofetil27$7,738
Gabapentin339$7,244
Carbamazepine ErCarbamazepine23$6,483
Pramipexole ErPramipexole Di-Hcl11$4,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$839$15,39721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →